Anoxic-Ischemic EncephalopathyHOPENCT02231060
Study for the Improvement of Long-Term Outcome Prediction in Patients in Coma After Cardiac Arrest
An observational study of Anoxic-Ischemic Encephalopathy, run by Ludwig-Maximilians - University of Munich at 16 sites in Germany.
Trial summary
The primary objective of HOPE is to improve the accuracy of outcome prediction in anoxic-ischemic encephalopathy following cardiac arrest by bringing under close scrutiny some of the existing methods used for this purpose (e.g. somato-sensory evoked potentials). Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Anoxic-Ischemic Encephalopathy
- How many people
- 150 participants
- Where
- 16 sitesGermany
- Study dates
- Oct 2014to 6 Dec 2018
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with anoxic-ischemic encephalopathy following cardiac arrest.
Who may be able to join
- Age between 18 and 85 years
- Cause of admission to ICU: cardiac arrest (in or out of hospital)
- Glasgow-Coma-Scale < 9 at time of study enrolment (3 to 8 days after cardiac arrest)
- Informed consent signed by legal guardian/next-of-kin
Who cannot join
- Stroke (as it may interfere with SSEP testing)
- Pre-existing coma/vegetative state/minimally conscious state
- Terminal malignant disease
- Survival in the next 12 months extremely unlikely
- Existing advanced directive that demands cessation of therapy/life support
- Palliative care/withdrawal of life support during treatment at the ICU
- Barbiturate-induced general anesthesia during the first 3 days after cardiac arrest
- Impossibility of assessing current level of consciousness with the Glasgow Coma Scale due to a long-term deep sedation
Trial locations and contacts
16 sites in 1 country.
16 sites in 1 country
Germany16 sites
Department of Neurology, Klinikum Augsburg
Augsburg, Bavaria, 86009
I. Medizinische Klinik, Klinikum Augsburg
Augsburg, Bavaria, 86009
Schön Klinik Bad Aibling
Bad Aibling, Bavaria, 83043
Dept of Neurology, Asklepios Stadtklinik Bad Tölz
Bad Tölz, Bavaria, 83646
Therapiezentrum Burgau
Burgau, Bavaria, 89331
Medizinische Klinik I und IV, Klinikum Ingolstadt
Ingolstadt, Bavaria, 85021
Neurologische Klinik, Klinikum Ingolstadt
Ingolstadt, Bavaria, 85021
Deutsches Herzzentrum Muenchen
Munich, Bavaria, 80636
Krankenhaus Barmherzige Brüder München
Munich, Bavaria, 80639
Schön Klinik München Schwabing
Munich, Bavaria, 80804
Department of Neurology, University of Munich
Munich, Bavaria, 81377
Internal ICU, Medical Clinic and Polyclinic IV, University of Munich
Munich, Bavaria, 81377
Medizinische Klinik und Poliklinik I, University of Munich
Munich, Bavaria, 81377
Department of Neurology
Munich, Bavaria, 81675
Clinic for Anesthesiology, University of Munich
Munich, Bavaria, D-81377
Neurologische Klinik, RoMed Klinikum Rosenheim
Rosenheim, Bavaria, 83022
About this study
Official title: Hypoxia and Outcome Prediction in Early Stage Coma: Towards an Improvement of Clinical and Electrophysiological Predictors
The primary objective of HOPE is to improve the accuracy of outcome prediction in anoxic-ischemic encephalopathy following cardiac arrest by bringing under close scrutiny some of the existing methods used for this purpose (e.g. somato-sensory evoked potentials). HOPE is the first multicenter prospective cohort study on coma prognosis to control for the effect of a possible self-fulfilling prophecy at the ICU and to cover the acute and neurorehabilitation phases with a long-term follow-up longer than the usual three or six months.
Read the detailed description
HOPE conducts a 2.5-year multicenter prospective cohort study in Germany on outcome prediction in the early stages of coma caused by cerebral hypoxia-ischemia.
The main features of the project are:
- Control for a self-fulfilling prophecy
- Long-term follow-up (12 months) covering acute and neurorehabilitation phases
- Use of sensitive measures of level of consciousness
- Further in-depth and systematic examination of the predictive value of somato-sensory evoked potentials (SSEP)
Using as a reference existing guidelines and previous research, we consider the following factors to be predictors of a negative outcome with a high specificity of > 90% with small 95% confidence intervals: loss of cortical N20 SEP potentials, loss of more than one brain stem reflex, non-reactive EEG, or a NSE above 33 mcg/L. We refer to the presence of any of these specific unfavourable test results during the ICU treatment as a "negative predictor". Therefore, our null hypothesis is that the probability of a favourable outcome, despite the presence of a negative predictor, is < 10%. We will use Simon's two-stage design. The null hypothesis will be tested against a one-sided alternative. In the first stage, we will accrue 72 patients. If there are 8 or fewer good outcomes in these 72 patients, the study will be discontinued because the null hypothesis could not be rejected. Otherwise, we will recruit 100 additional patients to gather a total of 172. The null hypothesis will be rejected if 28 or more favourable outcomes are observed in these 172 patients. This design yields a type I error rate of 0.05 and power of 80% if the true response rate is 25%, i.e. if indeed 25% or more patients have a favourable outcome despite a negative predictor. This calculation is based on the assumption that 25% of the enrolled patients have at least one negative predictor.
HOPE has seven data entry points (i.e. study visits).The primary endpoints are completion of the follow-up period or patient death. HOPE collects clinical and demographic data in accordance to Utstein-style recommendations. The most crucial part of the study is determining the current level of consciousness by means of the revised version of the Coma Recovery Scale (CRS-R). The CRS-R allows a precise categorization of the current level of consciousness based on a structured and systematic clinical examination of auditory, visual, motor, oromotor, communication and arousal functions. Other assessment instruments employed yield information about functional outcome/ADL, neuropsychological performance, and health-related quality of life.
Study centers will collect data prospectively following a data acquisition timeline (e.g. t0 to t6). Visits t0 to t2 will take place at acute-setting ICUs; visits t3 to t5 at neurorehabilitation centers; and visit t6 at the patients' location of residence 12 months after day 0. A manual and data dictionary will be provided to all centres along with the case report forms (CRF). All study centers will send pseudonymized data weekly by certified mail to the Central Study Centre (CSC) located at the Department of Neurology of the University of Munich. All study centres, including the CSC, will check the data for completeness, plausibility, accuracy, consistency and outliers. Legal representatives of coma patients, who decline to participate, will be asked to provide data on socio-demographic variables and reason for declining. The CSC will store the data at a database and will be responsible for safeguarding and analysing it. Patients/Legal representatives will be asked to remain in the study for a further follow-up. After completion of the follow-up period, datasets will be irreversibly anonymised.
We will analyze the positive predictive value of a dichotomous prognostic marker (favorable or unfavourable SSEP). For this purpose, we will use two definitions of favorable outcome, i.e. a functional and a behavioral one. If outcome is defined with respect to independence in daily life, we will use a modified Rankin Scale score of 0-3 (no symptoms - moderate disability, but able to walk independently) to categorize a favorable functional outcome. In the context of a catastrophic event such as cardiac arrest with high likelihood of permanent VS, it is our experience that some patients and families consider regaining functional communications skills also a favourable outcome. In a separate analysis, we will therefore use the recovery of full consciousness as measured by the CRS-R to define a favorable behavioral outcome. To analyse the effect of covariates on functional and behavioral outcomes, we will use mixed effects regression models, including both fixed and random effects. This method of analyzing longitudinal data is highly effective to examine change trajectories with several unequally spaced waves of data. Covariates will be sociodemographic variables, prognostic variables and treatment factors (e.g. use of therapeutic hypothermia), adjusted for age and sex.
- Conditions
- Anoxic-Ischemic Encephalopathy
- Keywords
- Outcome Prediction, Anoxic-Ischemic Encephalopathy, Coma, Vegetative State, Minimally Conscious State, Chronic Disorders of Consciousness
- Medical subject headings
- Hypoxia-Ischemia, Brain, Coma, Persistent Vegetative State
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| AIE after Cardiac Arrest | Male and female patients with AIE following CA. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Current level of consciousness as measured by the revised version of the Coma Recovery Scale (CRS-R)
The CRS-R allows a precise categorization of the current level of consciousness based on a structured and systematic clinical examination of auditory, visual, motor, oromotor, communication and arousal functions.
Measured: There are 6 CRS-R data entry points distributed within a 12-month period, namely, 2 time points at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
Secondary outcomes (1)
Regaining of functional communication skills and optimal health-related quality of life
Measured: Five data entry points distributed within a 12-month period, namely, 1 time point at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2014 (estimated)
- Study startOct 2014
- Primary completion6 Dec 2018
- Study completion6 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Anoxic-Ischemic EncephalopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (actual)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Sponsor type
- University, hospital or other
- Collaborators
- Else Kröner Fresenius Foundation, University Hospital Augsburg, Klinikum Ingolstadt, Klinikum Rosenheim, Therapiezentrum Burgau, Schoen Clinic Bad Aibling, Schön Klinik München Schwabing, Asklepios Stadtklinik Bad Tölz, Technical University of Munich, Krankenhaus Barmherzige Brüder München, Roteskreuzklinikum München, Deutsches Herzzentrum Muenchen
- Responsible party
- Principal investigator, Andreas Bender, Ludwig-Maximilians - University of Munich
- Investigators
- Andreas Bender, MD, Principal investigator, Ludwig-Maximilians-Universität München
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02231060
- Sponsor's protocol ID
- 2014_A55
- Acronym
- HOPE
- Status last verified
- Dec 2018
- First submitted
- 29 Aug 2014
- Last updated
- 12 Dec 2018
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Lopez-Rolon A, Bender A; Project HOPE Investigator Group. Hypoxia and Outcome Prediction in Early-Stage Coma (Project HOPE): an observational prospective cohort study. BMC Neurol. 2015 May 15;15:82. doi: 10.1186/s12883-015-0337-x.
PubMed 25971341Goetze D, Remi J, Leithner C, Diethei V, Fleischhauer V, Pauli B, Einhaeupl B, Luther T, Rosenfelder M, Lopez-Rolon A, Czermak S, Angstwurm MWA, Heck S, Zwissler B, Lohner H, Arva AL, Pfefferkorn T, Bluthgen A, Naumann M, Raake P, Schneider H, Ilg R, Muller F, Herzog J, Rauen K, Strobl R, Koller D, Grill E, Straube A, Bender A. Neuroprognostication after cardiac arrest in patients without withdrawal of life-sustaining therapy: a prospective observational multicenter study. Crit Care. 2026 Jul 24;30(1):391. doi: 10.1186/s13054-026-06209-0.
PubMed 42509572
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hypoxia and Outcome Prediction in Early Stage Coma: Towards an Improvement of Clinical and Electrophysiological Predictors
- ClinicalTrials.gov ID
- NCT02231060
- Acronym / sponsor ID
- HOPE / 2014_A55
- Conditions
- Anoxic-Ischemic Encephalopathy
- Keywords
- Outcome Prediction, Anoxic-Ischemic Encephalopathy, Coma, Vegetative State, Minimally Conscious State, Chronic Disorders of Consciousness
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Ludwig-Maximilians - University of MunichUniversity, hospital or other
- Collaborators
- Else Kröner Fresenius Foundation, University Hospital Augsburg, Klinikum Ingolstadt, Klinikum Rosenheim, Therapiezentrum Burgau, Schoen Clinic Bad Aibling, Schön Klinik München Schwabing, Asklepios Stadtklinik Bad Tölz, Technical University of Munich, Krankenhaus Barmherzige Brüder München, Roteskreuzklinikum München, Deutsches Herzzentrum Muenchen
- Study start
- Oct 2014
- Primary completion
- 6 Dec 2018 (actual)
- Study completion
- 6 Dec 2018 (actual)
- First posted
- 3 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of HOPE is to improve the accuracy of outcome prediction in anoxic-ischemic encephalopathy following cardiac arrest by bringing under close scrutiny some of the existing methods used for this purpose (e.g. somato-sensory evoked potentials). HOPE is the first multicenter prospective cohort study on coma prognosis to control for the effect of a possible self-fulfilling prophecy at the ICU and to cover the acute and neurorehabilitation phases with a long-term follow-up longer than the usual three or six months.
Detailed description
HOPE conducts a 2.5-year multicenter prospective cohort study in Germany on outcome prediction in the early stages of coma caused by cerebral hypoxia-ischemia.
The main features of the project are:
- Control for a self-fulfilling prophecy
- Long-term follow-up (12 months) covering acute and neurorehabilitation phases
- Use of sensitive measures of level of consciousness
- Further in-depth and systematic examination of the predictive value of somato-sensory evoked potentials (SSEP)
Using as a reference existing guidelines and previous research, we consider the following factors to be predictors of a negative outcome with a high specificity of > 90% with small 95% confidence intervals: loss of cortical N20 SEP potentials, loss of more than one brain stem reflex, non-reactive EEG, or a NSE above 33 mcg/L. We refer to the presence of any of these specific unfavourable test results during the ICU treatment as a "negative predictor". Therefore, our null hypothesis is that the probability of a favourable outcome, despite the presence of a negative predictor, is < 10%. We will use Simon's two-stage design. The null hypothesis will be tested against a one-sided alternative. In the first stage, we will accrue 72 patients. If there are 8 or fewer good outcomes in these 72 patients, the study will be discontinued because the null hypothesis could not be rejected. Otherwise, we will recruit 100 additional patients to gather a total of 172. The null hypothesis will be rejected if 28 or more favourable outcomes are observed in these 172 patients. This design yields a type I error rate of 0.05 and power of 80% if the true response rate is 25%, i.e. if indeed 25% or more patients have a favourable outcome despite a negative predictor. This calculation is based on the assumption that 25% of the enrolled patients have at least one negative predictor.
HOPE has seven data entry points (i.e. study visits).The primary endpoints are completion of the follow-up period or patient death. HOPE collects clinical and demographic data in accordance to Utstein-style recommendations. The most crucial part of the study is determining the current level of consciousness by means of the revised version of the Coma Recovery Scale (CRS-R). The CRS-R allows a precise categorization of the current level of consciousness based on a structured and systematic clinical examination of auditory, visual, motor, oromotor, communication and arousal functions. Other assessment instruments employed yield information about functional outcome/ADL, neuropsychological performance, and health-related quality of life.
Study centers will collect data prospectively following a data acquisition timeline (e.g. t0 to t6). Visits t0 to t2 will take place at acute-setting ICUs; visits t3 to t5 at neurorehabilitation centers; and visit t6 at the patients' location of residence 12 months after day 0. A manual and data dictionary will be provided to all centres along with the case report forms (CRF). All study centers will send pseudonymized data weekly by certified mail to the Central Study Centre (CSC) located at the Department of Neurology of the University of Munich. All study centres, including the CSC, will check the data for completeness, plausibility, accuracy, consistency and outliers. Legal representatives of coma patients, who decline to participate, will be asked to provide data on socio-demographic variables and reason for declining. The CSC will store the data at a database and will be responsible for safeguarding and analysing it. Patients/Legal representatives will be asked to remain in the study for a further follow-up. After completion of the follow-up period, datasets will be irreversibly anonymised.
We will analyze the positive predictive value of a dichotomous prognostic marker (favorable or unfavourable SSEP). For this purpose, we will use two definitions of favorable outcome, i.e. a functional and a behavioral one. If outcome is defined with respect to independence in daily life, we will use a modified Rankin Scale score of 0-3 (no symptoms - moderate disability, but able to walk independently) to categorize a favorable functional outcome. In the context of a catastrophic event such as cardiac arrest with high likelihood of permanent VS, it is our experience that some patients and families consider regaining functional communications skills also a favourable outcome. In a separate analysis, we will therefore use the recovery of full consciousness as measured by the CRS-R to define a favorable behavioral outcome. To analyse the effect of covariates on functional and behavioral outcomes, we will use mixed effects regression models, including both fixed and random effects. This method of analyzing longitudinal data is highly effective to examine change trajectories with several unequally spaced waves of data. Covariates will be sociodemographic variables, prognostic variables and treatment factors (e.g. use of therapeutic hypothermia), adjusted for age and sex.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AIE after Cardiac Arrest | – | –Male and female patients with AIE following CA. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with anoxic-ischemic encephalopathy following cardiac arrest.
Key inclusion criteria (4 listed)
- Age between 18 and 85 years
- Cause of admission to ICU: cardiac arrest (in or out of hospital)
- Glasgow-Coma-Scale < 9 at time of study enrolment (3 to 8 days after cardiac arrest)
- Informed consent signed by legal guardian/next-of-kin
Key exclusion criteria (8 listed)
- Stroke (as it may interfere with SSEP testing)
- Pre-existing coma/vegetative state/minimally conscious state
- Terminal malignant disease
- Survival in the next 12 months extremely unlikely
- Existing advanced directive that demands cessation of therapy/life support
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Current level of consciousness as measured by the revised version of the Coma Recovery Scale (CRS-R)
Time frame: There are 6 CRS-R data entry points distributed within a 12-month period, namely, 2 time points at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
The CRS-R allows a precise categorization of the current level of consciousness based on a structured and systematic clinical examination of auditory, visual, motor, oromotor, communication and arousal functions.
1 secondary outcome
Regaining of functional communication skills and optimal health-related quality of life
Time frame: Five data entry points distributed within a 12-month period, namely, 1 time point at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2018.
- Background: PubMed 25971341Lopez-Rolon A, Bender A; Project HOPE Investigator Group. Hypoxia and Outcome Prediction in Early-Stage Coma (Project HOPE): an observational prospective cohort study. BMC Neurol. 2015 May 15;15:82. doi: 10.1186/s12883-015-0337-x.
- Derived from this study: PubMed 42509572Goetze D, Remi J, Leithner C, Diethei V, Fleischhauer V, Pauli B, Einhaeupl B, Luther T, Rosenfelder M, Lopez-Rolon A, Czermak S, Angstwurm MWA, Heck S, Zwissler B, Lohner H, Arva AL, Pfefferkorn T, Bluthgen A, Naumann M, Raake P, Schneider H, Ilg R, Muller F, Herzog J, Rauen K, Strobl R, Koller D, Grill E, Straube A, Bender A. Neuroprognostication after cardiac arrest in patients without withdrawal of life-sustaining therapy: a prospective observational multicenter study. Crit Care. 2026 Jul 24;30(1):391. doi: 10.1186/s13054-026-06209-0.
- Hypoxia and Outcome Prediction in Early-Stage Coma (Project HOPE): an observational prospective cohort studyLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Anoxic-Ischemic Encephalopathy
RecruitingPhase 2
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
Hypoxia-Ischemia, Brain, Heart Arrest
RecruitingObservational study
Biomarkers Study in Infants With Prior Neonatal Brain Injury
HIE - Hypoxic - Ischemic Encephalopathy, Perinatal Anoxic-ischemic Brain Injury
Not yet recruitingPhase 2
Dexmedetomidine Versus Morphine During Cooling Therapy in Neonates
Hypoxic Ischemic Brain Injury, Neonatal Encephalopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andreas Bender, MD principal investigator
Ludwig-Maximilians-Universität München
16 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anoxic-Ischemic Encephalopathy, run by Ludwig-Maximilians - University of Munich at 16 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Current level of consciousness as measured by the revised version of the Coma Recovery Scale (CRS-R) (time frame: There are 6 CRS-R data entry points distributed within a 12-month period, namely, 2 time points at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02231060, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2018; AzTrials last refreshed its copy on 7 Nov 2026.